Based on long-term survival of patients with CML is "as soon as possible, according to the amount of long-term, regular medication". Sounds
Based on long-term survival of patients with CML is "as soon as possible, according to the amount of long-term, regular medication". Sounds like a simple request, but there are a lot of patients do not attach importance to the final cause of disease progression, Wei and life.
Immediately after diagnosis
CML is a hematological malignancy, after diagnosis should be started as soon as possible; because of CML is the abnormal chromosome translocation, fusion gene caused by the long-term low strength regular treatment may lead to resistance gene mutation, so it should be as soon as possible medication, strongly inhibited lesion of the fusion gene, and can maintain a stable remission of the disease for a long time, and eventually stop success medicine.
Every time the doctor will repeatedly stressed that the drug must be sufficient to eat, eat on time, eat for a long time. But how much to eat, or were "confused". If you do not remember the clinic, you can look at the following method of taking imatinib as an example:
The dose of adult patients with CML, the dose is the routine to take 4 tablets, eat once a day; taken with meals, and drink a glass of water; 4 pill not to split after the split dose, concentration of the drug in the blood will decline, will reduce the effect. The dose of children according to height and weight to calculate, note that children with rapid growth and development, which requires timely adjustment of drug dosage, otherwise it may lead to long-term inadequate treatment, eventually deteriorated;
Eat for a long time: in order to allow the disease to reach a long-term stable state, imatinib such drugs need long-term use. Patients should not stop taking drugs, regardless of how normal blood test results seem to be, how much decline in the number of fusion genes. The only person who can decide to reduce or even stop the drug is a qualified Department of Hematology doctor. Only adhere to the doctor's advice to take medicine, the condition may not progress, so as to ensure long-term survival.
Stop the premise is strictly follow the doctor's advice
Long term use of imatinib is costly, have a certain influence on the quality of life, therefore, CML patients are eager to have a day to stop drug and disease recurrence. Recent studies have confirmed that this desire has become a reality in some patients. "The depth of relief in the condition, the fusion gene quantitative value reached above 5 depth of the so-called MR (so-called" withdrawal threshold "), and maintained for more than two years, about 60% of the patients can stop imatinib treatment and disease remain stable. The depth of remission after treatment, there will be about 40% of recurrent disease. However, the study found that these patients who relapse after drug withdrawal, as long as the timely start of oral imatinib treatment, almost invariably again obtain stable remission. Although the information on the withdrawal is encouraging, but it should be emphasized that only under the strict supervision of the specialist, to enter the threshold of the withdrawal of patients can try this. Therefore, in order to achieve the "withdrawal threshold", still need to emphasize strictly adequate dosage and duration of medication after diagnosis, early only strictly follow the doctor's advice, will it be possible to enter the "withdrawal threshold", the final attempt to stop.
In order to prevent the leakage of the medication, patients should prepare special kits, seven days a week were installed in the corresponding box, every night to check the medication. At the same time suggested that patients take medicine regularly every day to develop a habit. Good treatment effect should be established on the basis of strict medication, if the patient forgot to take medicine in the morning, at noon or in the afternoon can be served according to the original dose, will not affect the second day of medication, but as far as possible do not leak.